Today, we are pleased to share an important development in our efforts to deliver hope for those living with #ALS. We owe it to them to do everything in our power to provide access to promising therapies as quickly as possible because they don’t have time to wait. 🧵
The continued analysis and the feedback received from the many scientific presentations of the Phase 3 data uncovered key insights that furthered our understanding of NurOwn's mechanism of action and potential as a treatment for ALS.
After carefully considering these learnings, the totality of the evidence from NurOwn’s clinical studies, and the feedback received from key opinion leaders and the broader ALS community, we will submit a Biologics License Application to @US_FDA.
The full dataset and careful analysis of NurOwn’s Phase 3 trial demonstrates the potential for #NurOwn as a treatment for ALS.
We are deeply grateful to the ALS clinical experts and members of the ALS community for their contribution to the development of NurOwn and what it may mean to those living with ALS
We are especially appreciative to @CIRMNews, @iamalsorg, @alsassociation, @DanaFarber, @cityofhope, @MGHNeurology @MayoClinic, @umassneurology, @CedarsSinai, @UCIrvine, and @SutterHealth for their partnership and tireless efforts.
A special thanks is reserved for all the clinical trial participants and their loved ones. Their sacrifices and contributions are advancing science and giving hope for a more promising future. 
Their commitment made our current progress possible and continue to inspire us as we prepare for the considerable work ahead. ir.brainstorm-cell.com/2022-08-15-Bra…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
